Jeffrey M. Jonas
Net Worth

Last updated:

What is Jeffrey M. Jonas net worth?

The estimated net worth of Dr. Jeffrey M. Jonas is at least $14,779,426 as of 10 Feb 2023. He owns shares worth $1,060,015 as insider, has earned $519,411 from insider trading and has received compensation worth at least $13,200,000 in Sage Therapeutics, Inc..

What is the salary of Jeffrey M. Jonas?

Dr. Jeffrey M. Jonas salary is $1,200,000 per year as Chief Innovation Officer, Chair of the Science & Technology Forum and Director in Sage Therapeutics, Inc..

How old is Jeffrey M. Jonas?

Dr. Jeffrey M. Jonas is 72 years old, born in 1953.

What stocks does Jeffrey M. Jonas currently own?

As insider, Dr. Jeffrey M. Jonas owns shares in one company:

Company Title Shares Price per share Total value
Sage Therapeutics, Inc. (SAGE) Chief Innovation Officer, Chair of the Science & Technology Forum and Director 121,981 $8.69 $1,060,015

What does Sage Therapeutics, Inc. do?

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SAGE logo
SAGE
Sage Therapeutics, Inc.
$8.69

Jeffrey M. Jonas insider trading

Sage Therapeutics, Inc.

Dr. Jeffrey M. Jonas has made 11 insider trades between 2014-2023, according to the Form 4 filled with the SEC. Most recently he sold 3,838 units of SAGE stock worth $172,330 on 10 Feb 2023.

The largest trade he's ever made was exercising 210,247 units of SAGE stock on 21 Dec 2017. As of 10 Feb 2023 he still owns at least 121,981 units of SAGE stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 3,838 $44.9 $172,330
Sale
Common Stock 7,805 $44.47 $347,081
Option
Stock Options (Right to buy) 11,643 $0.45 $5,239
Option
Common Stock 11,643 $0.45 $5,239
Option
Common Stock 2,501 $28.63 $71,604
Option
Stock Option (Right to Buy) 2,501 $28.63 $71,604
Option
Stock Option (Right to Buy) 30,944 $0.45 $13,925
Option
Common Stock 30,944 $0.45 $13,925
Option
Stock Option (Right to Buy) 4,000 $0.45 $1,800
Option
Common Stock 4,000 $0.45 $1,800
Option
Common Stock 12,000 $0.45 $5,400
Option
Stock Option (Right to Buy) 12,000 $0.45 $5,400
Option
Common Stock 1,800 N/A N/A
Option
Stock Option (Right to Buy) 1,800 N/A N/A
Purchase
Common Stock 7,500 N/A N/A
Option
Stock Option (Right to Buy) 4,600 N/A N/A
Option
Common Stock 4,600 N/A N/A
Option
Stock Option (Right to Buy) 27,000 N/A N/A
Option
Common Stock 27,000 N/A N/A
Sale
Common Stock 1,075 N/A N/A
Option
Stock Option (Right to Buy) 35,736 N/A N/A
Option
Common Stock 35,736 N/A N/A
Sale
Common Stock 84,661 N/A N/A
Option
Common Stock 40,356 N/A N/A
Option
Stock Option (Right to Buy) 40,356 N/A N/A
Sale
Common Stock 40,356 N/A N/A
Sale
Common Stock 53,908 N/A N/A
Option
Common Stock 53,908 N/A N/A
Option
Stock Option (Right to Buy) 53,908 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Stock Option (Right to Buy) 10,000 N/A N/A
Option
Stock Option (Right to Buy) 50,000 N/A N/A
Option
Common Stock 50,000 N/A N/A
Sale
Common Stock 12,753 N/A N/A
Option
Common Stock 12,753 N/A N/A
Option
Stock Option (Right to Buy) 12,753 N/A N/A
Option
Stock Option (Right to Buy) 110,247 N/A N/A
Option
Common Stock 110,247 N/A N/A
Sale
Common Stock 210,247 N/A N/A
Option
Common Stock 20,000 N/A N/A
Option
Stock Option (Right to Buy) 20,000 N/A N/A
Purchase
Common Stock 226 N/A N/A
Sale
Common Stock 3,000 N/A N/A
Sale
Common Stock 115,226 N/A N/A
Option
Common Stock 160,481 N/A N/A
Option
Stock Option (Right to Buy) 147,971 N/A N/A
Option
Common Stock 116,119 N/A N/A
Option
Stock Option (Right to Buy) 128,629 N/A N/A
Sale
Common Stock 83,374 N/A N/A
Purchase
Common Stock 6,000 N/A N/A

Sage Therapeutics key executives

Sage Therapeutics, Inc. executives and other stock owners filed with the SEC: